# Organogenesis Holdings Inc. (ORGO)

Source: https://www.quantisnow.com/company/ORGO
Generated: 2026-11-14T11:37:19.384Z

- Ticker: ORGO
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2016
- SEC CIK: 0001661181
- Website: organogenesis.com

## About

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic allograft wound covering and surgical barrier for application in the care of chronic and acute wounds or surgical implantation in spine, orthopedic, and sports medicine applications; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft, a dermal substitute for the treatment of DFUs; NuShield, a dehydrated placental tissue wound covering and surgical barrier applied to the target tissue to support native healing; and PuraPly Antimicrobial, an antimicrobial barrier skin substitute to treat chronic and acute wounds. Its surgical and sports medicine products comprise NuCel, a surgically implanted allograft used primarily in spinal and orthopedic surgical applications; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; Novachor, a chorionic membrane wound covering; TransCyte, a bioengineered tissue for the treatment of partial thickness burns; and Gintuit, a bioengineered bi-layered living cellular tissue for the treatment of mucogingival conditions in adults. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.

## Latest ORGO news and filings

- 2026-11-05 21:17 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Organogenesis Holdings Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-organogenesis-holdings-inc-6776725)
- 2026-11-05 21:10 UTC [SEC Form 8-K] [Organogenesis Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/organogenesis-holdings-inc-filed-sec-form-8-k-results-of-operations-6776487)
- 2026-11-05 21:05 UTC [Earnings] [Organogenesis Holdings Inc. Reports Third Quarter 2026 Financial Results](https://www.quantisnow.com/insight/organogenesis-holdings-inc-reports-third-quarter-2026-financial-results-6776177)
- 2026-10-12 20:10 UTC [Organogenesis Announces Publication of Peer-Reviewed PREPARE Trial Results Demonstrating Clinical Benefit of PuraPly®AM for Hard-to-Heal Diabetic Foot Ulcers](https://www.quantisnow.com/insight/organogenesis-announces-publication-of-peer-reviewed-prepare-trial-results-demonstrating-clinical-6743742)
- 2026-10-12 20:05 UTC [Earnings Date] [Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026](https://www.quantisnow.com/insight/organogenesis-holdings-inc-to-report-third-quarter-of-fiscal-year-6743714)
- 2026-08-06 20:45 UTC [SEC Form 8-K] [SEC Form 8-K filed by Organogenesis Holdings Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-organogenesis-holdings-inc-6669734)
- 2026-08-06 20:42 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Organogenesis Holdings Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-organogenesis-holdings-inc-6669707)
- 2026-08-06 20:15 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Organogenesis Holdings Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-organogenesis-holdings-inc-6669265)
- 2026-08-06 20:11 UTC [SEC Form 8-K] [Organogenesis Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/organogenesis-holdings-inc-filed-sec-form-8-k-results-of-operations-6669099)
- 2026-08-06 20:05 UTC [Earnings Date] [Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results](https://www.quantisnow.com/insight/organogenesis-holdings-inc-reports-second-quarter-2026-financial-results-6668641)
- 2026-07-27 20:05 UTC [Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers](https://www.quantisnow.com/insight/organogenesis-announces-publication-of-peer-reviewed-clinical-trial-results-demonstrating-clinical-6649586)
- 2026-07-09 12:16 UTC [One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics](https://www.quantisnow.com/insight/one-formula-one-platform-inside-the-preclinical-milestone-behind-conexeus-6632464)
- 2026-07-09 11:30 UTC [Earnings Date] [Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026](https://www.quantisnow.com/insight/organogenesis-holdings-inc-to-report-second-quarter-of-fiscal-year-6632341)
- 2026-07-06 20:05 UTC [Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis](https://www.quantisnow.com/insight/organogenesis-announces-fda-acceptance-of-biologics-license-application-for-renu-6628006)
- 2026-06-16 20:32 UTC [SEC Form 8-K] [Organogenesis Holdings Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/organogenesis-holdings-inc-filed-sec-form-8-k-leadership-update-6604975)
- 2026-06-16 14:30 UTC [The Quiet Revolution in Regenerative Medicine: From Replacing Tissue to Rebuilding It](https://www.quantisnow.com/insight/the-quiet-revolution-in-regenerative-medicine-from-replacing-tissue-to-6604300)
- 2026-06-02 13:00 UTC [The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts](https://www.quantisnow.com/insight/the-body-as-blueprint-a-recently-public-biotech-bets-that-6583540)
- 2026-05-28 12:57 UTC [Analyst Coverage Initiated] [Truist initiated coverage on Organogenesis with a new price target](https://www.quantisnow.com/insight/truist-initiated-coverage-on-organogenesis-with-a-new-price-target-6576406)
- 2026-05-08 12:46 UTC [Analyst Downgrade] [Organogenesis downgraded by BTIG Research](https://www.quantisnow.com/insight/organogenesis-downgraded-by-btig-research-6541250)
- 2026-05-07 20:16 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Organogenesis Holdings Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-organogenesis-holdings-inc-6539441)
- 2026-05-07 20:11 UTC [SEC Form 8-K] [Organogenesis Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/organogenesis-holdings-inc-filed-sec-form-8-k-results-of-operations-6539173)
- 2026-05-07 20:05 UTC [Earnings Date] [Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results](https://www.quantisnow.com/insight/organogenesis-holdings-inc-reports-first-quarter-2026-financial-results-6538885)
- 2026-04-30 20:17 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Organogenesis Holdings Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-organogenesis-holdings-inc-6524620)
- 2026-04-28 20:30 UTC [Organogenesis Completes Rolling Submission of Biologics License Application for ReNu®](https://www.quantisnow.com/insight/organogenesis-completes-rolling-submission-of-biologics-license-application-for-renu-6519002)
- 2026-04-25 01:29 UTC [SEC Form 4] [Chief Commercial Officer Grow Brian exercised 958 shares at a strike of $1.24, increasing direct ownership by 0.11% to 900,682 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-commercial-officer-grow-brian-exercised-958-shares-at-a-6515192)
- 2026-04-06 23:02 UTC [Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM](https://www.quantisnow.com/insight/organogenesis-achieves-primary-endpoint-in-randomized-controlled-trial-of-puraplyam-6489929)
- 2026-04-06 21:30 UTC [Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain](https://www.quantisnow.com/insight/organogenesis-announces-successful-fda-meeting-and-plan-to-file-bla-6489824)
- 2026-04-06 11:30 UTC [Earnings Date] [Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026](https://www.quantisnow.com/insight/organogenesis-holdings-inc-to-report-first-quarter-of-fiscal-year-6488634)
- 2026-03-12 01:45 UTC [Insider Buy] [Director Leibowitz Arthur S bought $13,405 worth of shares (5,000 units at $2.68), increasing direct ownership by 2% to 291,014 units (SEC Form 4)](https://www.quantisnow.com/insight/director-leibowitz-arthur-s-bought-13405-worth-of-shares-5000-6443133)
- 2026-03-11 21:45 UTC [Insider Buy] [Director Driscoll Michael Joseph bought $26,688 worth of shares (10,000 units at $2.67), increasing direct ownership by 5% to 225,707 units (SEC Form 4)](https://www.quantisnow.com/insight/director-driscoll-michael-joseph-bought-26688-worth-of-shares-10000-6442800)
- 2026-03-03 21:55 UTC [SEC Form 4] [Vice President, Strategy Cavorsi Robert covered exercise/tax liability with 700 shares, decreasing direct ownership by 0.25% to 275,524 units (SEC Form 4)](https://www.quantisnow.com/insight/vice-president-strategy-cavorsi-robert-covered-exercisetax-liability-with-700-6426151)
- 2026-02-26 21:15 UTC [SEC Form 10-K] [SEC Form 10-K filed by Organogenesis Holdings Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-organogenesis-holdings-inc-6416430)
- 2026-02-26 21:09 UTC [SEC Form 8-K] [Organogenesis Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/organogenesis-holdings-inc-filed-sec-form-8-k-results-of-operations-6416152)
- 2026-02-26 21:05 UTC [Earnings Date] [Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue](https://www.quantisnow.com/insight/organogenesis-holdings-inc-reports-fourth-quarter-2025-financial-results-posts-6415889)
- 2026-02-23 22:02 UTC [SEC Form 8-K] [SEC Form 8-K filed by Organogenesis Holdings Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-organogenesis-holdings-inc-6407848)
- 2026-02-20 22:29 UTC [SEC Form 4] [Chief Admin. and Legal Officer Freedman Lori was granted 245,905 shares and covered exercise/tax liability with 14,267 shares, increasing direct ownership by 29% to 1,023,355 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-admin-and-legal-officer-freedman-lori-was-granted-245905-6405473)
- 2026-02-20 22:28 UTC [SEC Form 4] [Vice President, Strategy Cavorsi Robert was granted 110,040 shares and covered exercise/tax liability with 5,432 shares, increasing direct ownership by 61% to 276,115 units (SEC Form 4)](https://www.quantisnow.com/insight/vice-president-strategy-cavorsi-robert-was-granted-110040-shares-and-6405472)
- 2026-02-20 22:28 UTC [SEC Form 4] [Chief Commercial Officer Grow Brian was granted 282,705 shares and covered exercise/tax liability with 11,768 shares, increasing direct ownership by 43% to 899,355 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-commercial-officer-grow-brian-was-granted-282705-shares-and-6405469)
- 2026-02-20 22:28 UTC [SEC Form 4] [Chief Financial Officer Francisco David covered exercise/tax liability with 14,541 shares and was granted 238,914 shares, increasing direct ownership by 44% to 731,020 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-francisco-david-covered-exercisetax-liability-with-14541-6405468)
- 2026-02-20 22:28 UTC [SEC Form 4] [Chief Operating Officer Bilbo Patrick was granted 259,549 shares and covered exercise/tax liability with 16,212 shares, increasing direct ownership by 28% to 1,127,985 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-operating-officer-bilbo-patrick-was-granted-259549-shares-and-6405466)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ORGO
- Earnings history: https://www.quantisnow.com/earnings/ORGO
- Dividend history: https://www.quantisnow.com/dividends/ORGO
- Insider transactions: https://www.quantisnow.com/insiders/ORGO
- Options chain: https://www.quantisnow.com/options/ORGO
- SEC 8-K filings only: https://www.quantisnow.com/company/ORGO/8-k
- RSS and alerts for ORGO: https://www.quantisnow.com/docs/rss-feeds.md